GlobeNewswire: CytomX Therapeutics Inc. Contains the last 10 of 234 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:13:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850174/0/en/CytomX-Therapeutics-Appoints-Dr-Zhen-Su-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors2024-03-21T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.]]>https://www.globenewswire.com/news-release/2024/03/18/2847747/0/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-PROBODY-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas2024-03-18T12:00:00Z<![CDATA[- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -]]>https://www.globenewswire.com/news-release/2024/03/11/2844158/0/en/CytomX-Therapeutics-Reports-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update2024-03-11T20:10:00Z<![CDATA[- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -]]>https://www.globenewswire.com/news-release/2024/03/04/2839546/0/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-11-2024.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 20242024-03-04T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.]]>https://www.globenewswire.com/news-release/2024/02/27/2835950/0/en/CytomX-Therapeutics-to-Present-at-Upcoming-March-Investor-Conferences.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics to Present at Upcoming March Investor Conferences2024-02-27T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in March.]]>https://www.globenewswire.com/news-release/2024/01/24/2815209/0/en/CytomX-Therapeutics-Announces-FDA-Clearance-of-IND-Applications-for-CX-2051-a-Probody-Antibody-Drug-Conjugate-ADC-Targeting-EpCAM-and-CX-801-a-Conditionally-Activated-Interferon-Al.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b2024-01-24T13:00:00Z<![CDATA[- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -]]>https://www.globenewswire.com/news-release/2024/01/12/2808578/0/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference2024-01-12T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/01/04/2803919/0/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Outlines 2024 Company Priorities and Milestones2024-01-04T13:00:00Z<![CDATA[- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 -]]>https://www.globenewswire.com/news-release/2023/12/21/2799945/0/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference2023-12-21T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT.]]>https://www.globenewswire.com/news-release/2023/11/07/2775653/0/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=27785CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-07T21:15:00Z<![CDATA[- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 -]]>